HomeCompareLJPC vs MO

LJPC vs MO: Dividend Comparison 2026

LJPC yields 32.31% · MO yields 6.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LJPC wins by $71.0K in total portfolio value
10 years
LJPC
LJPC
● Live price
32.31%
Share price
$6.19
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$151.1K
Annual income
$21,317.26
Full LJPC calculator →
MO
Altria Group Inc.
● Live price
6.36%
Share price
$65.99
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.1K
Annual income
$30,159.17
Full MO calculator →

Portfolio growth — LJPC vs MO

📍 LJPC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLJPCMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LJPC + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LJPC pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LJPC
Annual income on $10K today (after 15% tax)
$2,746.37/yr
After 10yr DRIP, annual income (after tax)
$18,119.67/yr
MO
Annual income on $10K today (after 15% tax)
$540.99/yr
After 10yr DRIP, annual income (after tax)
$25,635.29/yr
At 15% tax rate, MO beats the other by $7,515.62/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LJPC + MO for your $10,000?

LJPC: 50%MO: 50%
100% MO50/50100% LJPC
Portfolio after 10yr
$115.6K
Annual income
$25,738.21/yr
Blended yield
22.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

LJPC
No analyst data
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-7.2% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LJPC buys
0
MO buys
0
No recent congressional trades found for LJPC or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLJPCMO
Forward yield32.31%6.36%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$151.1K$80.1K
Annual income after 10y$21,317.26$30,159.17
Total dividends collected$106.0K$74.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: LJPC vs MO ($10,000, DRIP)

YearLJPC PortfolioLJPC Income/yrMO PortfolioMO Income/yrGap
1← crossover$13,931$3,231.02$10,570$780.30+$3.4KLJPC
2$19,113$4,206.67$11,381$1,032.90+$7.7KLJPC
3$25,845$5,393.83$12,535$1,392.73+$13.3KLJPC
4$34,470$6,816.44$14,193$1,920.91+$20.3KLJPC
5$45,380$8,496.64$16,618$2,723.68+$28.8KLJPC
6$59,010$10,453.99$20,263$3,993.80+$38.7KLJPC
7$75,846$12,704.70$25,936$6,098.36+$49.9KLJPC
8$96,416$15,261.03$35,166$9,775.01+$61.3KLJPC
9$121,296$18,130.84$51,026$16,597.78+$70.3KLJPC
10$151,104$21,317.26$80,113$30,159.17+$71.0KLJPC

LJPC vs MO: Complete Analysis 2026

LJPCStock

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts. As of August 22, 2022, La Jolla Pharmaceutical Company operates as a subsidiary of Innoviva, Inc.

Full LJPC Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this LJPC vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LJPC vs SCHDLJPC vs JEPILJPC vs OLJPC vs KOLJPC vs MAINLJPC vs PMLJPC vs BTILJPC vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.